This is a news story, published by USA Today, that relates primarily to The U.S. Food and Drug Administration news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from USA Today, you can click here:
more news from USA TodayOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
duloxetine drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest duloxetine news, nitrosoduloxetine news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
duloxetine capsulesUSA Today
•
70% Informative
More than 233,000 bottles of duloxetine capsules were voluntarily recalled on Nov. 19 .
The U.S. Food and Drug Administration assigned the recall as a class II risk.
The risk level is the FDA 's second most severe level as it could cause "temporary or medically reversible adverse health consequences" The medication had the "presence" of an impurity a potentially cancer-causing substance.
VR Score
49
Informative language
35
Neutral language
63
Article tone
semi-formal
Language
English
Language complexity
68
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
8
Affiliate links
no affiliate links